Royal Jelly Supplementation in Unexplained Male Infertility
Sponsored by Medipol University
About this trial
Last updated 4 months ago
Study ID
123123123123
Status
Not yet recruiting
Type
Interventional
Phase
N/A
Placebo
Yes
Accepting
18 to 45 Years
Male
Trial Timing
Started 4 months ago
What is this trial about?
This randomized, double-blind, placebo-controlled clinical trial investigates the effects of oral Royal Jelly supplementation on sperm DNA fragmentation and pregnancy rates in couples with unexplained infertility. While routine semen analysis appears normal (normozoospermia) in these patients, underlying Sperm DNA Fragmentation (SDF) and oxidative stress are believed to contribute to reproductive failure.
Participants will be randomized to receive either 750 mg of lyophilized Royal Jelly or a placebo daily for a period of 3 months (90 days). The study aims to evaluate whether the antioxidant properties of Royal Jelly can improve sperm chromatin integrity, reduce oxidative stress markers, and increase spontaneous pregnancy rates compared to the control group
What are the participation requirements?
Inclusion Criteria
* Men aged 18-45 years. History of infertility for at least 1 year despite unprotected intercourse.
Diagnosis of unexplained infertility with Normozoospermia according to WHO 2021 (6th Ed.) criteria:
Concentration ≥ 16 million/mL Total Motility ≥ 42% Progressive Motility ≥ 30% Normal Morphology (Kruger) ≥ 4% Female partner with normal gynecological evaluation (regular ovulation, normal ovarian reserve, and proven tubal patency via HSG).
Normal serum hormone levels (Testosterone, FSH, LH)
Exclusion Criteria
* Any abnormality in spermiogram (Oligo-, Asteno-, or Teratozoospermia). Presence of clinical varicocele. Leukocytospermia (>1 million/mL) or active infection. History of smoking (>5 cigarettes/day) or BMI > 30 kg/m². Use of any antioxidant supplementation within the last 3 months.